Caris Life Sciences raises FY‑2026 revenue outlook after 27% Q3 growth
Caris Life Sciences reported third‑quarter 2026 revenue of $275.4 million, a 27% year‑over‑year increase driven by molecular profiling services. Net income fell to $15.3 million (reported as $15.25 million in one source) while operating expenses rose sharply. The company lifted its full‑year 2026 revenue guidance to a range of $1.04 billion to $1.05 billion, reflecting 28%‑29% growth versus 2025.
Why it matters
The higher revenue outlook expands the market’s expectations for Caris’s top line, but the drop in profitability and higher expense forecast signal tighter near‑term cash generation, which could affect valuation and financing needs.
Key facts
- 1Q3 2026 revenue was $275.4 million, up 27% YoY. prnewswire.com
- 2Net income for the quarter was $15.3 million (reported as $15.25 million in another source). rttnews.com
- 3Operating expenses increased to $163 million, up $48.1 million from the prior year. finance.yahoo.com
- 4Full‑year 2026 revenue guidance was raised to $1.04 billion‑$1.05 billion, representing 28%‑29% growth versus 2025. prnewswire.com
- 5The company announced a share‑repurchase program of up to $100 million, with $72.1 million remaining authorized. prnewswire.com
- 6Free cash flow was negative $39.7 million in the quarter. finance.yahoo.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.